MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials (News-Medical-Net)

MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective.
(read the story…)

Related items

• Nanostart Majority-Owned MagForce Announces Successful Completion of Final Clinical Trials For Nano-Cancer® Therapy (Business Wire via Yahoo! Finance)
• Nanostart-Owned MagForce Nanotechnologies AG: Application Submitted For EU Regulatory Approval Of Nano-Cancer(R) Therapy (Medical News Today)
• MagForce Nanotechnologies applies for EU regulatory approval of its Nano-Cancer therapy (News-Medical-Net)
• MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study (Business Wire via Yahoo! Finance)
• MagForce Nanotechnologies AG Applies For European Regulatory Approval Of Its Nano-Cancer(R) Therapy (Medical News Today)

Tags: Berlin-based, brain tumor, cancer, cancer therapy, magforce, medical technology company, nano, Nano-Cancer, nanos, nanostart ag, nanotech, nanotechnologie, nanotechnologies, study, study objective, Technology

This entry was posted on Wednesday, November 4th, 2009 at 4:50 pm and is filed under Business.